SEC. 918. DRUG PRODUCTS USED TO TREAT tobacco DEPENDENCE.
(a) IN GENERAL.The Secretary shall(1) at the request of the applicant, consider designating products for smoking cessation, including nicotine replacement products as fast track research and approval products within the meaning of section 506; (2) consider approving the extended use of nicotine replacement products (such as nicotine patches, nicotine gum, and nicotine lozenges) for the treatment of tobacco dependence; and (3) review and consider the evidence for additional indications for nicotine replacement products, such as for craving relief or relapse prevention.
Section 918(a) (of the new tobacco product chapter of the FDCA) makes it unmistakably clear that Congress considers nicotine replacement products that are used for 'craving relief', 'smoking cessation', and 'relapse prevention', to be chapter V drug products used for the treatment of tobacco dependence.
Some nicotine replacement products (such as nicotine gum and nicotine lozenges) deliver nicotine via a non-tobacco excipient. Other NRPs (such as nicotine patches and the Nicotrol inhaler) deliver nicotine via a non-tobacco device. Thus, aside from the question of intended use, nicotine replacement products are products which deliver nicotine - in lieu of a tobacco product - via a non-tobacco excipient and/or a non-tobacco device. And in this respect, the e-cig (in being a non-tobacco device that delivers nicotine via a non-tobacco excipient) is a nicotine replacement product.
A manufacturer/importer may claim that its nicotine replacement product is not intended to be used for what Congress considers to be the therapeutic purposes of 'craving relief', 'smoking cessation', and/or 'relapse prevention'; but, if this was true, then what is it intended to be used for? Is it not self-evident that nicotine replacement products - by their very nature - are intended to relieve nicotine cravings in furtherance of the objective of ceasing and/or avoiding the use of tobacco? Is this not the reason why nicotine is taken out of tobacco and added to a non-tobacco excipient in the first place?
Even if the use of questionable disclaimers - and the avoidance of making therapeutic claims - would be sufficient to prevent the e-cig from being classified as a drug/device product on the basis of therapeutic intent, the very act of adding nicotine to their novel, smoke-simulating, non-tobacco excipient solutions demonstrates an intent of manufacturers to affect the structure or functions of the bodies (and brains) of those who will consume their product. Furthermore, it is this clear and undeniable intent (inherent in adding nicotine to a non-tobacco article or product) that is the rock-solid reason why NO nicotinated non-tobacco article or product has EVER escaped the drug-division domain of the FDA.
Congress may have adopted an expansive definition of the term 'tobacco product', but it also counter-balanced that definition with a definition of what is NOT a 'tobacco product': Section 201(rr)(2), "The term tobacco product does not mean an article that is a drug under subsection (g)(1), a device under subsection (h), or a combination product described in section 503(g)." And if the inherent therapeutic intent of nicotine replacement products is not enough to render the e-liquid/e-cig product a drug/device combination, then the undeniable intent inherent in adding nicotine to e-liquid is. Therefore, e-liquid (like every other nicotinated non-tobacco product) shall be regulated as a drug; and the e-cig, a device intended to be used with that drug. For, as Congress demands in the very next paragraph: Section 201(rr)(3), "The products described in paragraph (2) shall be subject to chapter V of this Act."
Note: This post marks the end of my contribution to the task of predicting the ruling that will matter.
(a) IN GENERAL.The Secretary shall(1) at the request of the applicant, consider designating products for smoking cessation, including nicotine replacement products as fast track research and approval products within the meaning of section 506; (2) consider approving the extended use of nicotine replacement products (such as nicotine patches, nicotine gum, and nicotine lozenges) for the treatment of tobacco dependence; and (3) review and consider the evidence for additional indications for nicotine replacement products, such as for craving relief or relapse prevention.
Section 918(a) (of the new tobacco product chapter of the FDCA) makes it unmistakably clear that Congress considers nicotine replacement products that are used for 'craving relief', 'smoking cessation', and 'relapse prevention', to be chapter V drug products used for the treatment of tobacco dependence.
Some nicotine replacement products (such as nicotine gum and nicotine lozenges) deliver nicotine via a non-tobacco excipient. Other NRPs (such as nicotine patches and the Nicotrol inhaler) deliver nicotine via a non-tobacco device. Thus, aside from the question of intended use, nicotine replacement products are products which deliver nicotine - in lieu of a tobacco product - via a non-tobacco excipient and/or a non-tobacco device. And in this respect, the e-cig (in being a non-tobacco device that delivers nicotine via a non-tobacco excipient) is a nicotine replacement product.
A manufacturer/importer may claim that its nicotine replacement product is not intended to be used for what Congress considers to be the therapeutic purposes of 'craving relief', 'smoking cessation', and/or 'relapse prevention'; but, if this was true, then what is it intended to be used for? Is it not self-evident that nicotine replacement products - by their very nature - are intended to relieve nicotine cravings in furtherance of the objective of ceasing and/or avoiding the use of tobacco? Is this not the reason why nicotine is taken out of tobacco and added to a non-tobacco excipient in the first place?
Even if the use of questionable disclaimers - and the avoidance of making therapeutic claims - would be sufficient to prevent the e-cig from being classified as a drug/device product on the basis of therapeutic intent, the very act of adding nicotine to their novel, smoke-simulating, non-tobacco excipient solutions demonstrates an intent of manufacturers to affect the structure or functions of the bodies (and brains) of those who will consume their product. Furthermore, it is this clear and undeniable intent (inherent in adding nicotine to a non-tobacco article or product) that is the rock-solid reason why NO nicotinated non-tobacco article or product has EVER escaped the drug-division domain of the FDA.
Congress may have adopted an expansive definition of the term 'tobacco product', but it also counter-balanced that definition with a definition of what is NOT a 'tobacco product': Section 201(rr)(2), "The term tobacco product does not mean an article that is a drug under subsection (g)(1), a device under subsection (h), or a combination product described in section 503(g)." And if the inherent therapeutic intent of nicotine replacement products is not enough to render the e-liquid/e-cig product a drug/device combination, then the undeniable intent inherent in adding nicotine to e-liquid is. Therefore, e-liquid (like every other nicotinated non-tobacco product) shall be regulated as a drug; and the e-cig, a device intended to be used with that drug. For, as Congress demands in the very next paragraph: Section 201(rr)(3), "The products described in paragraph (2) shall be subject to chapter V of this Act."
Note: This post marks the end of my contribution to the task of predicting the ruling that will matter.